NextGen restructures management as it gears up for assay launches
This article was originally published in Clinica
Biomarker specialist NextGen Sciences (Ann Arbor, Michigan) has appointed Neal Siegel to the new role of director of assay development. Dr Siegel, who previously worked at Sword Diagnostics and Abbott Labs, will oversee assay delivery, validation and quality control at NextGen. The company has also appointed Glenn Barney vice-president of business development. Formerly of Decision Biomarkers, Mr Barney will help drive sales growth across all NextGen products. He will also lead the firm’s marketing activities, and will be joined by the new director of marketing, Hiroshi Saito, who joins from internet and digital marketing agency Optiem. The new appointments come as NextGen prepares to launch two new biomarker assays markets in the first half of this year; one is a human plasma assay targeting several oncology disease areas, and the other is a human cerebrospinal fluid assay for central nervous system disorders.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.